Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects

Abstract Anti-vascular endothelial growth factor (anti-VEGF) therapies have become the standard of care in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), resulting in a remarkable decrease in disease-related vision loss. However, the need for r...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Justus G. Garweg, Claudine A. Blum, René-Pierre Copt, Chiara M. Eandi, Katja Hatz, Christian F. Prünte, Eleonora Seelig, Gábor M. Somfai
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Adis, Springer Healthcare 2023-01-01
Reeks:	Ophthalmology and Therapy
Onderwerpen:	Brolucizumab Diabetic macular edema (DME) Intraocular inflammation (IOI) Neovascular age-related macular degeneration (nAMD) Retinal vascular occlusion Retinal vasculitis
Online toegang:	https://doi.org/10.1007/s40123-023-00647-7
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!